Inhibrx reported positive registrational phase II results for ozekibart in advanced or metastatic, unresectable chondrosarcoma, meeting its primary endpoint with a statistically significant improvement in median progression‑free survival. The data mark a rare late‑stage success in a hard‑to‑treat, low‑patient‑volume indication and have prompted management to plan a Biologics License Application (BLA) submission targeted for the second half of 2026. Investors reacted swiftly, sending the company’s stock sharply higher intraday on the topline readout.